share_log

復星醫藥:於二零二四年九月二十七日(星期五)舉行的二零二四年第一次臨時股東大會所提呈決議案的投票結果及選舉非執行董事

FOSUN PHARMA: POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 27 SEPTEMBER 2024 AND ELECTION OF NON-EXECUTIVE DIRECTOR

HKEX ·  Sep 27, 2024 19:59

Summary by Futu AI

復星醫藥於2024年9月27日成功舉行了該年度第一次臨時股東大會,會議在上海天禧嘉福璞緹客酒店召開。會上,陳玉卿先生被正式選舉為第九屆董事會非執行董事,並將自當日起生效至本屆董事會任期結束。此外,股東大會亦審議並通過了修訂公司章程及其附件的特別決議案。在股權登記日,復星醫藥已發行股份總數為2,672,398,711股,其中A股和H股分別為2,120,458,211股及551,940,500股。出席大會的股東或其代表共持有1,089,723,630股表決權股份,佔有表決權股份總數的比例為40.9351%。會議由董事長吳以芳先生主持,並有11位在任董事出席。臨時股東大會的召集、召開程序及表決結果均獲法律意見認為合法有效。陳玉卿先生的選舉獲得絕大多數股東支持,贊成票數超過半數,而修訂公司章程的特別決議案則獲得超過三分之二的贊成票。陳先生持有公司134,000股A股及20,000股H股,並無需從公司收取任何酬金。
復星醫藥於2024年9月27日成功舉行了該年度第一次臨時股東大會,會議在上海天禧嘉福璞緹客酒店召開。會上,陳玉卿先生被正式選舉為第九屆董事會非執行董事,並將自當日起生效至本屆董事會任期結束。此外,股東大會亦審議並通過了修訂公司章程及其附件的特別決議案。在股權登記日,復星醫藥已發行股份總數為2,672,398,711股,其中A股和H股分別為2,120,458,211股及551,940,500股。出席大會的股東或其代表共持有1,089,723,630股表決權股份,佔有表決權股份總數的比例為40.9351%。會議由董事長吳以芳先生主持,並有11位在任董事出席。臨時股東大會的召集、召開程序及表決結果均獲法律意見認為合法有效。陳玉卿先生的選舉獲得絕大多數股東支持,贊成票數超過半數,而修訂公司章程的特別決議案則獲得超過三分之二的贊成票。陳先生持有公司134,000股A股及20,000股H股,並無需從公司收取任何酬金。
fosun pharma successfully held its first interim shareholders' meeting of the year on September 27, 2024, which took place at the Shanghai Tianxi Jiafu Puti Ke Hotel. During the meeting, Mr. Chen Yuqing was formally elected as a non-executive director of the ninth board of directors, effective from that day until the end of the current term of the board of directors. In addition, the shareholders' meeting also reviewed and passed a special resolution to amend the company's articles of association and its appendices. On the record date, fosun pharma had a total issued share capital of 2,672,398,711 shares, with 2,120,458,211 shares of A shares and 551,940,500 shares of H shares. Shareholders or their representatives attending the meeting collectively hold 1,089,723,630 voting shares, accounting...Show More
fosun pharma successfully held its first interim shareholders' meeting of the year on September 27, 2024, which took place at the Shanghai Tianxi Jiafu Puti Ke Hotel. During the meeting, Mr. Chen Yuqing was formally elected as a non-executive director of the ninth board of directors, effective from that day until the end of the current term of the board of directors. In addition, the shareholders' meeting also reviewed and passed a special resolution to amend the company's articles of association and its appendices. On the record date, fosun pharma had a total issued share capital of 2,672,398,711 shares, with 2,120,458,211 shares of A shares and 551,940,500 shares of H shares. Shareholders or their representatives attending the meeting collectively hold 1,089,723,630 voting shares, accounting for 40.9351% of the total voting shares. The meeting was chaired by Mr. Wu Yifang, the chairman, and attended by 11 current directors. The convening, procedures, and voting results of the interim shareholders' meeting were deemed legally valid by legal opinions. Mr. Chen Yuqing's election received overwhelming support from the vast majority of shareholders, with affirmative votes exceeding the majority, while the special resolution to amend the company's articles of association received over two-thirds of the affirmative votes. Mr. Chen holds 134,000 A shares and 20,000 H shares in the company, and does not require any remuneration from the company.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.